A hydrophilic polymer comprising pendent groups of the formula I: Wherein: W is independently selected from —OH, —COOH, —SO.sub.3H, —OPO.sub.3H, —O—(C.sub.1-4alkyl), —O—(C.sub.1-4alkyl)OH, —O—(C.sub.1-4alkyl)R.sup.2, —O—(C.sub.2H.sub.5O).sub.qR.sup.1—(C═O)—O—C.sub.1-4alkyl and —O—(C═O)C.sub.1-4alkyl; or a group —BZ; wherein —OH, COOH, O—PO.sub.3H and SO.sub.3H maybe in the form of a pharmaceutically acceptable salt; wherein: B is a bond, or a straight branched alkanediyl, oxyalkylene, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and Z is an ammonium, phosphonium, or sulphonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; G is a coupling group through which the group of the formula I is coupled to the polymer and is selected from ether, ester, amide, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane; R.sup.1 is H or C.sub.1-4 alkyl; R.sup.2 is —COOH, —SO.sub.3H, or —OPO.sub.3H.sub.2 q is an integer from 1 to 4; n is an integer from 1 to 4; p is an integer from 1 to 3; and n+p is from 2 to 5; and wherein —COOH, —OPO.sub.3H.sub.2 and —SO.sub.3H as well as phenolic —OH maybe in the form of a pharmaceutically acceptable salt.

An adhesive device for biomedical applications is provided comprising a support and one or more water insoluble compounds of structure 1 wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-triol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4 or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. Structure 1

An adhesive device for biomedical applications is provided comprising a support and one or more water insoluble compounds of structure 1 wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-triol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4 or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. Structure 1

The present disclosure provides a technique capable of ensuring good visibility when introducing an embolic agent and reducing the visibility after introduction. Provided is an embolic agent kit. The embolic agent kit includes: a catheter having an inner cavity; a reaction product of an ethylenically unsaturated monomer and a crosslinking agent, which is filled in the inner cavity; and a priming solution containing a visualization agent and configured to prime an inside of the catheter.

The present disclosure provides a technique capable of ensuring good visibility when introducing an embolic agent and reducing the visibility after introduction. Provided is an embolic agent kit. The embolic agent kit includes: a catheter having an inner cavity; a reaction product of an ethylenically unsaturated monomer and a crosslinking agent, which is filled in the inner cavity; and a priming solution containing a visualization agent and configured to prime an inside of the catheter.

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for embolizing vasculature including the neurovasculature within a patient, among many other uses.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

An object of the present invention is to provide a hemostatic method, a vascular occlusion method, a tissue covering method, and a body fluid coagulation method that are safe and efficient using a polymer material that is a non-biologically derived synthetic product.

A solution (pre-gel solution) is prepared that contains, under a specific concentration condition, a hydrophilic polymer capable of forming a hydrogel by intermolecular crosslinking and has a specific pH condition and specific ionic strength, and the solution is gelled in situ in an environment, such as a bleeding site or the interior of a blood vessel, where blood is present.

An object of the present invention is to provide a hemostatic method, a vascular occlusion method, a tissue covering method, and a body fluid coagulation method that are safe and efficient using a polymer material that is a non-biologically derived synthetic product.

A solution (pre-gel solution) is prepared that contains, under a specific concentration condition, a hydrophilic polymer capable of forming a hydrogel by intermolecular crosslinking and has a specific pH condition and specific ionic strength, and the solution is gelled in situ in an environment, such as a bleeding site or the interior of a blood vessel, where blood is present.